Z

Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267

Watchlist Manager
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Watchlist
Price: 8.29 CNY -0.96%
Market Cap: 9.7B CNY
Have any thoughts about
Zhejiang Hisun Pharmaceutical Co Ltd?
Write Note

Zhejiang Hisun Pharmaceutical Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang Hisun Pharmaceutical Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Accrued Liabilities
ÂĄ409.9m
CAGR 3-Years
7%
CAGR 5-Years
12%
CAGR 10-Years
7%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accrued Liabilities
ÂĄ2B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accrued Liabilities
ÂĄ620.1m
CAGR 3-Years
74%
CAGR 5-Years
53%
CAGR 10-Years
31%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accrued Liabilities
ÂĄ128.5m
CAGR 3-Years
456%
CAGR 5-Years
130%
CAGR 10-Years
63%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accrued Liabilities
ÂĄ1.5B
CAGR 3-Years
74%
CAGR 5-Years
54%
CAGR 10-Years
46%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accrued Liabilities
ÂĄ146m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Hisun Pharmaceutical Co Ltd
Glance View

Market Cap
10B CNY
Industry
Pharmaceuticals

Zhejiang Hisun Pharmaceutical Co., Ltd. unfolds its story in the competitive arena of China's booming pharmaceutical industry. Founded in 1956, Hisun has gradually matured from a regional player into a recognized name in global generic and specialty drug manufacturing. The company's core strength lies in its integration across the pharmaceutical supply chain, which allows it to produce active pharmaceutical ingredients (APIs) while also scaling up to final dosage forms. Hisun capitalizes on its robust research and development capabilities, investing heavily in innovation to expand its diverse pharmaceutical product portfolio. Through strategic partnerships and collaborative ventures, such as alliances with leading biotech firms, Hisun not only enhances its technological footprint but fortifies its international presence, poised to address the increasing global demand for affordable healthcare solutions. In the sprawling marketplace, Hisun’s financial model is driven by its synergistic blend of producing generic medications and investing in biopharmaceuticals. The firm enjoys a lucrative revenue stream by tapping into the cost-effective production of APIs, which are integral to numerous medications worldwide. Through vertically integrated operations, the company achieves economies of scale, facilitating competitive pricing. Hisun’s foray into more value-added, complex generics and biosimilars further diversifies its income channels, transforming challenges into opportunities amid stringent global regulatory landscapes. By navigating these complexities, Hisun strengthens its market position, leveraging a balance between solid internal growth and strategic global outreach, thus sustaining its journey within the dynamic panorama of the pharmaceutical sector.

Intrinsic Value
13.13 CNY
Undervaluation 37%
Intrinsic Value
Price
Z

See Also

What is Zhejiang Hisun Pharmaceutical Co Ltd's Accrued Liabilities?
Accrued Liabilities
409.9m CNY

Based on the financial report for Sep 30, 2024, Zhejiang Hisun Pharmaceutical Co Ltd's Accrued Liabilities amounts to 409.9m CNY.

What is Zhejiang Hisun Pharmaceutical Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
7%

Over the last year, the Accrued Liabilities growth was 34%. The average annual Accrued Liabilities growth rates for Zhejiang Hisun Pharmaceutical Co Ltd have been 7% over the past three years , 12% over the past five years , and 7% over the past ten years .

Back to Top